Published in final edited form as:

Curr Neurol Neurosci Rep. 2014 January ; 14(1): 422. doi:10.1007/s11910-013-0422-8.

Arterial Ischemic Stroke in Children: Risk Factors and Etiologies

Adam L. Numis⁽¹⁾ and Christine K. Fox⁽¹⁾

Adam L. Numis: numisa@neuropeds.ucsf.edu; Christine K. Fox: foxc@neuropeds.ucsf.edu

⁽¹⁾Division of Child Neurology, University of California, San Francisco. 675 Nelson Rising Lane, 402 B, San Francisco, CA 94143, USA; Tel: 415-502-7303; fax: 415-476-2500

Abstract

Stroke is increasingly recognized as a significant cause of morbidity or mortality in children and as a financial burden for families and society. Recent studies have identified and confirmed presumptive risk factors and have identified novel associations with childhood arterial ischemic stroke. A better understanding of these risk factors for stroke in children, which differ from the atherosclerotic risk factors in adults, is the first step needed to improve strategies for stroke prevention and intervention and ultimately minimize the physical, mental and financial burden of AIS. Here, we discuss recent advances in research for selected childhood stroke risk factors, highlighting the progress made in our understanding of etiologic mechanisms and pathophysiology, and address the future directions for acute and long-term treatment strategies for pediatric stroke.

Keywords

Pediatric stroke; cerebral arteriopathy; cranial radiation; sickle cell disease; congenital heart disease; patent foramen ovale

Introduction

Stroke has become an increasingly recognized cause of morbidity and mortality in children. Population-based studies of arterial ischemic stroke (AIS) in children (defined by age 29 days to 18 years) estimate an annual incidence of 2.4 per 100,000 persons with a case fatality rate approaching 4% [1, 2]. Hospitalizations for AIS in children have been rising in the past decade [3, 4]. Over 50% of survivors have persistent neurologic, cognitive or psychiatric deficits, with significant financial costs to families and society [5–9]. Epilepsy develops in nearly a third of young stroke survivors within the first decade after stroke, which may place further strain on families caring for child with disabilities [10].

The rising rates of pediatric AIS hospitalization may be related in part to the increasing availability and use of better diagnostic techniques, such as Magnetic Resonance Imaging (MRI) [11]. An improving public stroke awareness and recognition of stroke symptoms may also contribute. Finally, incidence rates of childhood stroke may actually be rising as the

Correspondence to: Christine K. Fox, foxc@neuropeds.ucsf.edu.

Conflict of Interest

Adam L. Numis declares that he has no conflict of interest.

Christine K. Fox has received pediatric stroke research grants while an Assistant Professor, Division of Child Neurology, at the University of California, San Francisco.

Compliance with Ethics Guidelines

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

prevalence of important stroke risk factors in children change over time. Traditional cardiovascular risk factors of obesity and hypertension are becoming more prevalent among children at younger ages [12, 13]. Concurrently, the prevalence of diabetes, hypertension, lipid disorders, alcohol abuse, and tobacco use has increased among both adolescents and young adults hospitalized with AIS [4]. The prevalence of congenital heart disease in adolescents hospitalized with AIS has also increased, perhaps reflecting improvement in the overall care and longer survival of children with cardiac anomalies, who then may be vulnerable to stroke as a delayed complication. On a more hopeful note, the prevalence of sickle cell disease has decreased among children with AIS as effective stroke prevention strategies have become available and are implemented [14, 15].

In contrast to adults, in whom modifiable risk factors such as cigarette smoking, hypertension, diabetes, and hypercholesterolemia have been well-documented, risk factors for pediatric AIS are less well understood. Traditional pediatric stroke risk factors were initially identified in case series describing the high prevalence of congenital heart disease, sickle cell disease, infection and hyper-coagulable states among children with stroke [16–18]. As with other uncommon conditions, studies of childhood stroke have often been limited by sample size. Recently, the International Pediatric Stroke Study (IPSS), a multi-center, international observational cohort study reported on the prevalence of a spectrum of medical conditions associated with 676 children with AIS across broad geographical regions [19, 20]. This prospective, collaborative, international effort is the largest series of childhood strokes to date and has provided greater details on presumptive childhood AIS risk factors. However, the children in this study remain a selected population enrolled predominantly from tertiary pediatric centers. The Kaiser Pediatric Stroke Study (KPSS), a population-based, case-control study, provides complementary data, confirming estimates of stroke risk in 2.5 million children and young adults in a single geographic region, Northern California (Table 1) [21, 22]. Identifying and quantifying risk factors for childhood AIS allows focused future research in stroke mechanisms for specific stroke etiologies.

Pediatric stroke is still an emerging field of study, and the recent literature identifying and confirming childhood stroke risk factors are of great importance. Yet, only about half of the children with a stroke have an underlying condition that predisposes to stroke, and etiology remains undetermined in a significant number of children even after workup. Further, many of the risk factors discussed in this review may overlap or have a common mechanism. For example, cerebral arteriopathy is a leading mechanism for childhood stroke, but may be the result of various underlying genetic conditions such as sickle cell disease, PHACE syndrome or fibromuscular dysplasia, an acquired condition from trauma or infection, or develop in a previously healthy child without any other known risk factors. In this review, we discuss recent advances in research for selected childhood stroke risk factors, highlighting the progress made in our understanding of etiologic mechanisms and pathophysiology, and address the future directions for acute and long-term treatment strategies for pediatric stroke.

An Evolving Understanding of Children at Risk for Ischemic Stroke

Congenital Heart Disease

Cardiac anomalies, both congenital and acquired, are reported in a large proportion of children with stroke. In the Great Ormond Hospital series, 15% of children had a history of cardiac disorder prior to stroke. In the IPSS, 31% were reported to have a cardiac disorder. In contrast, only of the 8% of the children in KPSS had a history of congenital heart disease. This discrepancy may reflect differences between series from primarily tertiary referral centers and population-based data. Abnormal cardiac anatomy may increase risk of AIS through a number of mechanisms including paradoxical shunting of emboli, a prothrombotic state secondary to inflammation, iron-deficient anemia and depressed cardiac function [23,

24]. Cardiopulmonary bypass, circulatory arrest or other factors related to cardiac surgical repair may also be mediators of increased stroke risk [25, 26].

The use of new pediatric-specific ventricular assist devices and smaller extracorporeal life support systems has risen over the past decade for children with congenital heart disease, serving as a bridge to transplant or recovery [27]. As care for children with complex congenital heart disease has increased overall life expectancy, more children are surviving into adulthood. Both before and after surgical repair, children with CHD may be susceptible to acquired conditions such as infective endocarditis or arrhythmias [28]. Stroke remains a long-term risk, particularly in patients with cyanotic heart lesions [29]. In a cohort of 135 patients with congenital heart disease and incident stroke, 27% had stroke recurrence by 10 years of follow-up [30]. Over half of those with stroke recurrence were already on treatment with antiplatelet agents and/or anticoagulation, emphasizing the need for optimization of therapeutic strategies in this population.

The importance of patent foramen ovale (PFO) for cryptogenic stroke in the young has received much recent attention. A PFO acts a potential right to left shunt, and may allow venous emboli to reach the brain. However, an isolated PFO was reported in only 5% of children in the IPSS as compared to prevalence of approximately a quarter of the general population [19, 31, 32]. The role of an isolated PFO in otherwise cryptogenic childhood stroke remains unclear, and the efficacy of closure of a PFO to prevent recurrent stroke has been hotly debated. Recently, the RESPECT (Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment) trial evaluated PFO closure versus medical therapy alone in 980 adults with PFO and a recent diagnosis of cryptogenic ischemic stroke and found no significant benefit of PFO closure in preventing recurrent ischemic stroke in their primary analysis [33]. However, PFO closure was superior to medical therapy in the per-protocol and as-treated secondary endpoints. Serious adverse event rates were similar between the groups, and subgroup analyses suggested that those with substantial shunt size or atrial septal aneurysm might have an increased benefit. In similarly designed randomized trials, the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients with a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism through a Patent Foramen Ovale) trial and the PC Trial (Clinical Trial Comparing Percutaneous Closure of the Patent Foramen Ovale Using the Amplatzer PFO Occluder with Medical Treatment in Patients with Cryptogenic Embolism) there were no significant differences in stroke recurrence rates between the PFO closure versus medical therapy groups [34, 35]. What these results mean for young adults with cryptogenic stroke remains open to interpretation, and extrapolation of that interpretation to children is even less clear. The mean age of patients in all three trials was around 45 years, and both CLOSURE I and RESPECT excluded children under 18. In the PC trial, the younger participants (under 45 years), showed a trend towards benefit from PFO closure. Further trials are underway that may clarify which, if any groups might benefit PFO closure after AIS. However, no registered trials include participants less than 16 years of age, limiting generalizability of results to children [36, 37].

Infection

Preceding infections are reported in a large proportion of childhood strokes. In KPSS, children with a minor infection in the preceding month had a greater than four-fold increase in risk of AIS compared to controls [22]. In IPSS, infection was associated with 24% of AIS cases and the prevalence was inversely proportionate to age, with those under 5 years at most risk [19]. No single location of infection was more likely to be associated with AIS; and cases had varied illnesses including upper respiratory infection, acute otitis media and acute gastroenteritis [22].

The mechanisms for AIS during, or after an infection are actively under investigation. Several studies have correlated major infections such as meningitis and sepsis, as well as minor infections with risk of AIS in adults. [38–41]. In KPSS, a recent upper respiratory infection was noted in 9% of those with a cerebral arteriopathy, compared to 5% of those without an arteriopathy. This association was stronger when comparing children with a unilateral, intracranial arterial stenosis or focal cerebral arteriopathy (FCA) to those with other arteriopathy (e.g., dissection, moyamoya, sickle cell) [42]. Pathologic changes in post-mortem tissue of patients with infection and AIS have given credence to a role for inflammation. Varicella zoster virus-related arteriopathy is perhaps the best-studied example of a direct vascular infection in association with AIS. Post-mortem tissue in post-varicella arteriopathy and AIS has demonstrated virus in sections of vessel intima and associated lymphocytic cellular infiltration and vascular proliferation [43–46]. Prospective studies are underway to better understand the complex association of infection, inflammation, cerebral vascular injury, and AIS [47].

Trauma

Trauma has been associated with stroke in adults and has been reported as a prevalent exposure preceding stroke in children. In KPSS, a medical encounter for head or neck trauma in the 12 weeks prior to stroke was found in 12% of cases but only 1.6% of controls [22]. Though the median time from trauma to AIS was 0.5 days, risk of stroke persisted through three months after the event. Frequent causes of injury in children with AIS include motor-vehicle accidents, gunshot wounds, non-accidental trauma, and sports-related injuries [22]. The major physiologic mechanisms of stroke after head and neck trauma are thought to be stretching or tearing of the vertebral or carotid arteries from sudden and forceful hyperextension and contralateral rotation of the head, a direct blow to the neck or orbit or laceration by adjacent fractures. Resulting dissection, arteriovenous fistula or pseudoaneurysms ultimately interrupt blood flow or causes artery-to-artery thromboembolic events to the brain [48, 49]. In the current paradigm, patients thought to be at risk for cerebrovascular injury after trauma receive vascular imaging. If a vascular abnormality is found, treatment with an anti-platelet agent or anti-coagulation is initiated to prevent stroke. However, important questions remain unanswered. Screening protocols for cerebrovascular injury after blunt trauma in adult populations are based on expert opinion with data from case-series in large trauma hospitals [50, 51]. Evidence guiding when, how and who to screen for vascular injury in pediatric trauma populations is even more limited [51]. In a large retrospective, single-institution study of children less than 18 years of age with blunt trauma screened with Computed Tomography Angiography (CTA), 0.3% of patients were diagnosed with cerebrovascular injury. In this group, 28% of asymptomatic children would have not met adult guidelines for a screening CTA when the adult screening criteria after blunt trauma were applied [52]. Population-based investigations in pediatric cohorts with trauma are needed to identify specific risk factors of cerebrovascular injury and stroke, ascertain the ideal imaging modality for screening and best practices for intervention to prevent stroke.

The pathogenesis of AIS after mild trauma is less clear and may be related to the vulnerable cerebral anatomy present in childhood in combination with an additional risk factor, such as prior CNS infection, resulting in a milieu where subtle shear or stretch can result in intimal lesions and thrombosis [53, 54]. A subset of children may be susceptible to vertebral artery dissection and posterior circulation stroke after minor trauma due to congenital bony and ligamentous abnormalities. Anatomic variations including arcuate foramen, atlanto-axial subluxation, fibrous soft tissue bands, or acquired bony lesions may compress the vertebral artery during head rotation [55–59]. From limited studies, an estimated 4% of the population is thought to significantly compress or occlude one of their vertebral arteries during head

rotation vertebral artery compression [60, 61]; and, with head turning has been well described as a cause of vertebrobasilar insufficiency in adults. More rarely, posterior circulation strokes occur in children due to chronic vertebral artery dissection at the level of rotational vertebral artery compression [55, 58, 59, 62]. In a series of 12 children with posterior circulation strokes, nine were found ultimately to have unilateral or bilateral arcuate foramen though to contribute to their stroke findings [55].

Sickle cell disease

Children with sick cell anemia (SCA) are at risk of stroke due to the development of progressive large vessel cerebral vasculopathy, moyamoya disease and, possibly, a higher likelihood of intracardiac shunting [63]. Without treatment, the estimated incidence rate is 1 in 416 person-years, with a prevalence of 11% by 20 years of age [64, 65]. In 1992, abnormal transcranial Doppler (TCD) examination of the middle cerebral artery or internal cerebral artery (timed average mean maximum velocity > 200 cm/sec) was found to predict stroke. Among children who had abnormal TCD screening velocities, 40% had a stroke within three years [66, 5]. This finding led to the landmark STOP trial, which found chronic blood transfusion therapy in patients with abnormal TCD velocities reduced primary stroke risk by 92% [14, 67]. Exactly how chronic blood transfusion confers stroke protection is not known, but is thought to be through improvement or halting progression of large vessel cerebral arteriopathy [68]. Typically, these large vessel stenoses affect the distal internal carotid artery, the proximal portions of the middle and anterior cerebral arteries, and can be radiographically evident through imaging with Magnetic Resonance Angiography (MRA), CTA and conventional cerebral angiograms. Stenotic, diseased vessel lumen can be a nidus for thrombus formation and artery to artery emboli or decrease cerebral perfusion leading to watershed ischemia. Children with severe stenosis experience recurrent transient ischemic attacks as the blood to the brain is more and more compromised, ultimately leading to ischemic stroke or, later in the disease, hemorrhage from these abnormal, delicate collateral vessels [69].

To develop better alternatives for stroke prevention, it has become increasingly important to understand the pathophysiology behind focal cerebral stenosis in sickle cell disease. While incompletely understood, recent research suggests a complex, causal pathway involving chronic intravascular hemolysis, release of pro-inflammatory mediators, activation of endothelial surface, and endothelial dysfunction [70, 71]. Free hemoglobin from chronic hemolysis and reduction of nitric oxide availability are thought to lead to increased vasomotor tone [72]. Adherent erythrocytes, leukocytes and platelets further contribute to the inflammatory milieu, leading to endothelial damage and proliferation of smooth muscle cells [73]. Post-mortem examinations of cerebral arteries after AIS demonstrate intimal thickening with fibroblast and smooth muscle proliferation in larger arteries with resultant thrombus [74, 75]. In states of chronic anemia, and particularly in vascular territories of diseased stenotic vessels with decreased flow, the brain reacts by auto-regulation of the cerebrovasculature, with blood vessel dilation and increased blood flow to improve perfusion. When episodes of systemic stress lead to sickling, the brain receives a double hit of both increased metabolic demand and decreased oxygen carrying capacity. Blood vessels with a proximal stenosis that are already near maximum dilation have little reserve and are vulnerable to watershed ischemia. Finally, children with SCA may be at increased risk of stroke via a higher prevalence of cardiac shunting. In a single center childhood stroke cohort, children with SCA had twice the prevalence of PFO compared to children without SCA, suggesting a possible vulnerability to paradoxical embolism in addition to cerebral vasculopathy [76].

Because chronic transfusions confer the long-term health risks of infection, iron overload and end-organ damage, alternative methods to reduce stroke risk have been studied. The

SWITCH trial (Stroke with Transfusions Changing to Hydroxyurea) was initiated to study stroke reduction after transitioning from chronic transfusion to hydroxyurea, an anti-neoplastic agent that increases hemoglobin F levels [77]. In this non-inferiority trial, 134 children with SCA, history of stroke, and over 18 months of prior blood transfusions were randomized to receive 30 months of hydroxyurea and phlebotomy (to relieve established iron overload) or continued blood transfusions with chelation therapy. In a planned interim analysis after one-third of subjects completed trial exit, there was a 10% stroke recurrence rate in the hydroxyurea/phlebotomy group and 0% in the transfusion/chelation group. Moreover, they found no change in liver iron stores between the groups, and the trial was closed early because of safety concerns. Additional roles for hydroxyurea in stroke prevention for children with SCA continue to be studied. A randomized clinical trial comparing hydroxyurea to chronic blood transfusions for the primary prevention of stroke in SCA is underway in the TWITCH trial (TCD with Transfusions Changing to Hydroxyurea) [78].

Cancer

As survival rates of childhood cancers has improved, so too has our understanding of the long-term effects of radiation therapy. Regardless of underlying malignancy, cranial and cervical radiation increases risk of AIS [79–82]. In 2006, the Childhood Cancer Survivor Study (CCSS) measured a six-fold increase in relative risk of stroke for childhood leukemia survivors compared to sibling controls. Survivors of brain tumors had a nearly 30-fold increased relative risk of stroke compared to siblings [79]. A recent retrospective review of children with CNS malignancy who had received cranial and cervical radiation demonstrated a stroke incidence rate of 2% at 5 years and 4% at 10 years [80]. The risk for AIS in this population persists well into adulthood, with an increase in AIS risk of nearly eight-fold compared to matched sibling controls in the CCSS cohort after an average of 18.6 years from oncologic diagnosis to AIS [83]. Risk factors for stroke include administration of therapy to the Circle of Willis and escalating doses of radiation [80, 84, 79, 85]. As with other diseases discussed in this review, the mechanism of arterial injury and vasculopathy after radiation therapy is not well understood. Hypotheses include oxidative stress with chronic inflammation and resultant accelerated atherosclerosis [86, 87].

Currently, the Children's Oncology Group Long-Term Follow-Up Guidelines recommend annual neurologic examinations in those who received over 18 Gray (Gy) of cranial radiation [88]. However, there are no consensus guidelines for treatment of vasculopathy or the use of neuroimaging as a screening tool in asymptomatic patients. An ongoing prospective study of MRI and MRA annually after cranial radiation may improve understanding of the temporal development of vasculopathy, a first step towards primary and secondary stroke prevention strategies in children treated for cancer.

Hypercoagulable states

Many genetic and acquired thrombophilias have been associated with incident AIS in childhood [16, 19, 89] and elevated lipoprotein (a) has recently been associated with recurrent childhood stroke [90]. Thrombophilias are relatively common in the general population and are often thought to interact with other risk factors in a multi-factorial manner in children who have had a stroke. The association of MTHFR polymorphism homozygosity, elevated homocysteine and risk of thromboembolic events are debated [91]. Because the effect of MTHFR mutation is mediated through hyperhomocysteinemia, which may be overcome through a folate rich diet, fasting homocysteine levels is a more appropriate test for thrombotic risk. While management strategies for thrombosis are relatively well defined in adults, recommendations are less clear for children. With the possible exception of anti-phospholipid anti-body testing, the indications for and benefit of

extensive screening for thrombophilia after stroke in children is controversial, particularly because it is unclear how results should alter management. Further studies are needed to evaluate the role of genetic polymorphisms and stroke risk in children, optimize screening practices, and evaluate potential therapeutic strategies for those who may be at increased risk.

Management of AIS

Hyperacute Therapies

When presenting early after a stroke, adult patients have several hyperacute interventional options available that have been studied for efficacy of clot lysis, restoration of brain perfusion and long-term outcomes, including intravenous or intra-arterial administration of tissue plasminogen activator (tPA) and endovascular clot retrieval devices. However, children under 18 have generally been excluded from hyper-acute stroke interventional studies. In the absence of age-appropriate safety data or dosing guidelines, children who present with an acute stroke are sometimes treated with hyperacute therapy outside of the recommended guidelines for use of tPA. A recent case series of mechanical embolectomy in children with AIS described successful revascularization in four children, ages 4–17 years with large-vessel AIS, using the Merci retriever (Concentric Medical, Mountain View, California, USA) and/or Penumbra system (Penumbra, Alameda, California, USA) with concomitant clinical improvement [92]. The median time from stroke onset to arterial puncture ranged from 4 to 20 hours. In keeping with adult trials, they observed a 25% rate of asymptomatic intracranial hemorrhage [93]. Currently, the international multicenter study entitled “Thrombolysis in Pediatric Stroke”, or TIPS is enrolling children ages 2–17 years with clinically, and radiographically confirmed AIS within three hours of symptom onset to assess dose-determination, safety and efficacy of IV tPA [94]. Additionally, the study will assess the safety and efficacy of intra-arterial (IA) tPA in eligible patients three to six hours after symptoms onset. This critical study will help guide the use of tPA in pediatric cohorts.

Secondary Stroke Prevention

Chronic transfusions are a mainstay for both primary and secondary stroke prevention in SCA [77]. Beyond this, optimal strategies for secondary stroke prevention in children are debated. After a stroke, children are often treated with anticoagulation or anti-platelet therapy to prevent recurrence. Additional therapies, such as surgical revascularization, are considered for secondary stroke prevention in severe moyamoya arteriopathies, which may be familial, idiopathic or related to sickle cell disease, neurofibromatosis type 1, and Down syndrome [95–97]. Choice of therapy and duration of treatment are generally guided by the mechanism of injury, presence of comorbidities and a provider’s estimate of recurrence risk. Except in SCA, no randomized controlled clinical trials are available to guide practice. Within the IPSS, children post-stroke were treated with anti-coagulation alone in 27% compared to anti-platelet alone in 28% of cases. Practice varied geographically and was associated with stroke etiology [98]. Current treatment practices are based on expert opinion and consensus guidelines that are often extrapolated from data in adult stroke trials. The risk and benefit of anti-coagulation and antiplatelets therapy likely varies by age and underlying stroke etiology; therefore further age-specific research for stroke prevention in children should be a priority. Finally, for pediatric stroke research to move forward, further development and validation of systems of stroke classification and outcome scales are essential. The validation of the Pediatric National Institutes of Health Stroke Scale from chart review may allow comparable outcome measures across retrospective studies [99]. Uniform classification of pediatric stroke etiologies using the Childhood AIS Standardized Classification and Diagnostic Evaluation (CASCADE) criteria will be critical to future prospective studies targeting interventions for prevention of stroke recurrence [100].

Conclusions

Awareness of the risk of stroke in the young may be improving with the advent of social media, increase in disease-focused websites, and increase in trained sub-specialists. As the appreciation of AIS in pediatric populations grows, so too will our ability to study and understand this potentially devastating illness. Already, the established association of sickle cell disease with AIS has allowed for improvement in therapeutic strategies for primary stroke. Understanding the association of infection or radiation with childhood stroke has begun to shed light on the role of arteriopathies in AIS. Ultimately, advancements in the identification of pediatric populations most at risk for stroke will improve and hasten diagnosis, allowing for targeted studies of stroke prevention.

References

1. Agrawal N, Johnston SC, Wu YW, et al. Imaging data reveal a higher pediatric stroke incidence than prior US estimates. *Stroke*. 2009; 40:3415–21. [PubMed: 19762687]
2. Fox CK, Johnston SC, Sidney S, Fullerton HJ. High critical care usage due to pediatric stroke: results of a population-based study. *Neurology*. 2012; 79:420–7. [PubMed: 22744664]
3. Gandhi SK, McKinney JS, Sedjro JE, et al. Temporal trends in incidence and long-term case fatality of stroke among children from 1994 to 2007. *Neurology*. 2012; 78:1923–9. [PubMed: 22649219]
4. George MG, Tong X, Kuklina EV, Labarthe DR. Trends in stroke hospitalizations and associated risk factors among children and young adults, 1995–2008. *Annals of neurology*. 2011; 70:713–21. [PubMed: 21898534]
5. Hajek CA, Yeates KO, Anderson V, et al. Cognitive Outcomes Following Arterial Ischemic Stroke in Infants and Children. *J Child Neurol*. 2013
6. Cnossen MH, Aarsen FK, Akker S, et al. Paediatric arterial ischaemic stroke: functional outcome and risk factors. *Dev Med Child Neurol*. 2010; 52:394–9. [PubMed: 20089051]
7. Pavlovic J, Kaufmann F, Boltshauser E, et al. Neuropsychological problems after paediatric stroke: two year follow-up of Swiss children. *Neuropediatrics*. 2006; 37:13–9. [PubMed: 16541363]
8. Steinlin M, Roellin K, Schroth G. Long-term follow-up after stroke in childhood. *Eur J Pediatr*. 2004; 163:245–50. [PubMed: 14986120]
9. Gardner MA, Hills NK, Sidney S, et al. The 5-year direct medical cost of neonatal and childhood stroke in a population-based cohort. *Neurology*. 2010; 74:372–8. [PubMed: 20054007]
10. Fox CK, Glass HC, Sidney S, et al. Acute seizures predict epilepsy after childhood stroke. *Ann Neurol*. 2013
11. Smith-Bindman R, Miglioretti DL, Larson EB. Rising use of diagnostic medical imaging in a large integrated health system. *Health Aff (Millwood)*. 2008; 27:1491–502. [PubMed: 18997204]
12. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. *JAMA*. 2012; 307:483–90. [PubMed: 22253364]
13. Rosner B, Cook NR, Daniels S, Falkner B. Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988–2008. *Hypertension*. 2013; 62:247–54. [PubMed: 23856492]
14. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. *N Engl J Med*. 1998; 339:5–11. [PubMed: 9647873]
15. McCavit TL, Xuan L, Zhang S, et al. National trends in incidence rates of hospitalization for stroke in children with sickle cell disease. *Pediatr Blood Cancer*. 2013; 60:823–7. [PubMed: 23151905]
16. Ganesan V, Prengler M, McShane MA, et al. Investigation of risk factors in children with arterial ischemic stroke. *Ann Neurol*. 2003; 53:167–73. [PubMed: 12557282]
17. Mancini J, Girard N, Chabrol B, et al. Ischemic cerebrovascular disease in children: retrospective study of 35 patients. *J Child Neurol*. 1997; 12:193–9. [PubMed: 9130094]
18. Lanthier S, Carmant L, David M, et al. Stroke in children: the coexistence of multiple risk factors predicts poor outcome. *Neurology*. 2000; 54:371–8. [PubMed: 10668698]

- 19•. Mackay MT, Wiznitzer M, Benedict SL, et al. Arterial ischemic stroke risk factors: the International Pediatric Stroke Study. *Ann Neurol*. 2011; 69:130–40. This prospective, international series includes 676 children with arterial ischemic stroke (AIS) and identifies several presumptive risk factors for AIS including arteriopathies, congenital heart disease, and infection stratified by age and geographic region. [PubMed: 21280083]
20. Golomb MR, Fullerton HJ, Nowak-Gottl U, Deveber G. Male predominance in childhood ischemic stroke: findings from the international pediatric stroke study. *Stroke*. 2009; 40:52–7. [PubMed: 18787197]
21. Fullerton HJ, Wu YW, Sidney S, Johnston SC. Risk of recurrent childhood arterial ischemic stroke in a population-based cohort: the importance of cerebrovascular imaging. *Pediatrics*. 2007; 119:495–501. [PubMed: 17332202]
- 22•. Hills NK, Johnston SC, Sidney S, et al. Recent trauma and acute infection as risk factors for childhood arterial ischemic stroke. *Ann Neurol*. 2012; 72:850–8. This retrospective population based study within the Kaiser Permanente Medical Care Program of Northern California included a cohort of 126 children with arterial ischemic stroke (AIS) and identified risk factors for AIS. They found a four-fold increase in AIS in the four weeks after a medical encounter for a minor acute infection, and a nine-fold increase in the 12 weeks after a head or neck trauma. [PubMed: 23280836]
23. Maguire JL, deVeber G, Parkin PC. Association between iron-deficiency anemia and stroke in young children. *Pediatrics*. 2007; 120:1053–7. [PubMed: 17974743]
24. Procelewska M, Kolcz J, Januszewska K, et al. Coagulation abnormalities and liver function after hemi-Fontan and Fontan procedures - the importance of hemodynamics in the early postoperative period. *Eur J Cardiothorac Surg*. 2007; 31:866–72. [PubMed: 17329113]
25. Bellinger DC, Jonas RA, Rappaport LA, et al. Developmental and neurologic status of children after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass. *N Engl J Med*. 1995; 332:549–55. [PubMed: 7838188]
26. Manlhiot C, Menjak IB, Brandao LR, et al. Risk, clinical features, and outcomes of thrombosis associated with pediatric cardiac surgery. *Circulation*. 2011; 124:1511–9. [PubMed: 21911785]
27. Almond CS, Morales DL, Blackstone EH, et al. Berlin Heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. *Circulation*. 2013; 127:1702–11. [PubMed: 23538380]
28. Niwa K, Nakazawa M, Tateno S, et al. Infective endocarditis in congenital heart disease: Japanese national collaboration study. *Heart*. 2005; 91:795–800. [PubMed: 15894782]
29. Hoffmann A, Chockalingam P, Balint OH, et al. Cerebrovascular accidents in adult patients with congenital heart disease. *Heart*. 2010; 96:1223–6. [PubMed: 20639238]
30. Rodan L, McCrindle BW, Manlhiot C, et al. Stroke recurrence in children with congenital heart disease. *Ann Neurol*. 2012; 72:103–11. [PubMed: 22829272]
31. Dowling MM, Hynan LS, Lo W, et al. International Paediatric Stroke Study: stroke associated with cardiac disorders. *Int J Stroke*. 2012
32. Meissner I, Khandheria BK, Heit JA, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. *J Am Coll Cardiol*. 2006; 47:440–5. [PubMed: 16412874]
- 33•. Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. *N Engl J Med*. 2013; 368:1092–100. This prospective, multicenter, randomized trial of 980 adults with cryptogenic ischemic stroke and history of patent foramen ovale (PFO) compared medical therapy alone to PFO closure. They found no difference in recurrent ischemic stroke between the groups in their primary endpoint in an intention-to-treat analysis. They report a significant decrease in events after PFO closure compared to medical therapy alone in their prespecified per-protocol and as-treated analyses. [PubMed: 23514286]
- 34•. Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. *N Engl J Med*. 2012; 366:991–9. This prospective, multicenter, randomized trial of 908 adults with cryptogenic ischemic stroke or TIA and history of patent foramen ovale (PFO) compared medical therapy alone to PFO closure. They found no significant difference in recurrent stroke, TIA, or death from neurologic causes between the groups after two years of follow-up. [PubMed: 22417252]

35. Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. *N Engl J Med*. 2013; 368:1083–91. This prospective, multicenter, randomized trial of 414 participants less than 60 years of age with patent foramen ovale (PFO) and cryptogenic ischemic stroke, transient ischemic attack or peripheral thromboembolism compared medical therapy alone to PFO closure. They found no significant difference in recurrent stroke or TIA between the groups after five years of follow-up. [PubMed: 23514285]
36. Assistance Publique-Hôpitaux de Paris. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2000. Closure of Patent Foramen Ovale or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence. Internet cited 2013 Sep 18 Available from: <http://clinicaltrials.gov/show/NCT00562289> NLM Identifier: NCT00562289
37. Dowling MM, Ikemba CM. Intracardiac shunting and stroke in children: a systematic review. *J Child Neurol*. 2011; 26:72–82. [PubMed: 21212453]
38. Grau AJ, Buggle F, Becher H, et al. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia: clinical and biochemical studies. *Neurology*. 1998; 50:196–203. [PubMed: 9443480]
39. Bova IY, Bornstein NM, Korczyn AD. Acute infection as a risk factor for ischemic stroke. *Stroke*. 1996; 27:2204–6. [PubMed: 8969781]
40. Vergouwen MD, Schut ES, Troost D, van de Beek D. Diffuse cerebral intravascular coagulation and cerebral infarction in pneumococcal meningitis. *Neurocrit Care*. 2010; 13:217–27. [PubMed: 20526697]
41. Weststrate W, Hijdra A, de Gans J. Brain infarcts in adults with bacterial meningitis. *Lancet*. 1996; 347:399. [PubMed: 8598723]
42. Amlie-Lefond C, Bernard TJ, Sebire G, et al. Predictors of cerebral arteriopathy in children with arterial ischemic stroke: results of the International Pediatric Stroke Study. *Circulation*. 2009; 119:1417–23. [PubMed: 19255344]
43. Berger TM, Caduff JH, Gebbers JO. Fatal varicella-zoster virus antigen-positive giant cell arteritis of the central nervous system. *Pediatr Infect Dis J*. 2000; 19:653–6. [PubMed: 10917225]
44. Hayman M, Hendson G, Poskitt KJ, Connolly MB. Postvaricella angiopathy: report of a case with pathologic correlation. *Pediatr Neurol*. 2001; 24:387–9. [PubMed: 11516617]
45. Hausler MG, Ramaekers VT, Reul J, et al. Early and late onset manifestations of cerebral vasculitis related to varicella zoster. *Neuropediatrics*. 1998; 29:202–7. [PubMed: 9762696]
46. Moriuchi H, Rodriguez W. Role of varicella-zoster virus in stroke syndromes. *Pediatr Infect Dis J*. 2000; 19:648–53. [PubMed: 10917224]
47. Fullerton HJ, Elkind MS, Barkovich AJ, et al. The vascular effects of infection in Pediatric Stroke (VIPS) Study. *J Child Neurol*. 2011; 26:1101–10. [PubMed: 21616922]
48. Griessenauer CJ, Fleming JB, Richards BF, et al. Timing and mechanism of ischemic stroke due to extracranial blunt traumatic cerebrovascular injury. *J Neurosurg*. 2013; 118:397–404. [PubMed: 23216467]
49. Fabian TC, George SM Jr, Croce MA, et al. Carotid artery trauma: management based on mechanism of injury. *J Trauma*. 1990; 30:953–61. discussion 61–3. [PubMed: 2388306]
50. Bromberg WJ, Collier BC, Diebel LN, et al. Blunt cerebrovascular injury practice management guidelines: the Eastern Association for the Surgery of Trauma. *J Trauma*. 2010; 68:471–7. [PubMed: 20154559]
51. Wang AC, Charters MA, Thawani JP, et al. Evaluating the use and utility of noninvasive angiography in diagnosing traumatic blunt cerebrovascular injury. *J Trauma Acute Care Surg*. 2012; 72:1601–10. [PubMed: 22695428]
52. Jones TS, Burlew CC, Kornblith LZ, et al. Blunt cerebrovascular injuries in the child. *Am J Surg*. 2012; 204:7–10. [PubMed: 22172317]
53. Yang FH, Wang H, Zhang JM, Liang HY. Clinical features and risk factors of cerebral infarction after mild head trauma under 18 months of age. *Pediatr Neurol*. 2013; 48:220–6. [PubMed: 23419473]
54. Nabika S, Kiya K, Satoh H, et al. Ischemia of the internal capsule due to mild head injury in a child. *Pediatr Neurosurg*. 2007; 43:312–5. [PubMed: 17627149]

55. Cushing KE, Ramesh V, Gardner-Medwin D, et al. Tethering of the vertebral artery in the congenital arcuate foramen of the atlas vertebra: a possible cause of vertebral artery dissection in children. *Dev Med Child Neurol*. 2001; 43:491–6. [PubMed: 11463182]
56. Dadsetan MR, Skerhut HE. Rotational vertebrobasilar insufficiency secondary to vertebral artery occlusion from fibrous band of the longus coli muscle. *Neuroradiology*. 1990; 32:514–5. [PubMed: 2287384]
57. Hasan I, Wapnick S, Tenner MS, Couldwell W. Vertebral artery dissection in children: a comprehensive review. *Pediatr Neurosurg*. 2002; 37:168–77. [PubMed: 12372909]
58. Lu DC, Gupta N, Mummaneni PV. Minimally invasive decompression of a suboccipital osseous prominence causing rotational vertebral artery occlusion. Case report. *J Neurosurg Pediatr*. 2009; 4:191–5. [PubMed: 19772401]
59. Saito K, Hirano M, Taoka T, et al. Artery-to-artery embolism with a mobile mural thrombus due to rotational vertebral artery occlusion. *J Neuroimaging*. 2010; 20:284–6. [PubMed: 19021833]
60. Faris AA, Poser CM, Wilmore DW, Agnew CH. Radiologic visualization of neck vessels in healthy men. *Neurology*. 1963; 13:386–96. [PubMed: 13944384]
61. Sakaguchi M, Kitagawa K, Hougaku H, et al. Mechanical compression of the extracranial vertebral artery during neck rotation. *Neurology*. 2003; 61:845–7. [PubMed: 14504337]
62. Fox Christine, K.; SCE; Nalin, Gupta; Lawton Michael, T.; Dowd Christopher, F.; Fullerton Heather, J. Posterior Circulation Stroke in Children Due to Cervical Spine Abnormalities. American Heart Association/American Stroke Association International Stroke Conference and Nursing Symposium; February 2103; Honolulu, Hawaii. 2013. p. A77
63. Dowling MM, Lee N, Quinn CT, et al. Prevalence of intracardiac shunting in children with sickle cell disease and stroke. *J Pediatr*. 2010; 156:645–50. [PubMed: 20022343]
64. Earley CJ, Kittner SJ, Feaser BR, et al. Stroke in children and sickle-cell disease: Baltimore-Washington Cooperative Young Stroke Study. *Neurology*. 1998; 51:169–76. [PubMed: 9674798]
65. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. *Blood*. 1998; 91:288–94. [PubMed: 9414296]
66. Adams RJ, Nichols FT, Figueroa R, et al. Transcranial Doppler correlation with cerebral angiography in sickle cell disease. *Stroke*. 1992; 23:1073–7. [PubMed: 1636180]
67. Adams RJ, McKie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. *Ann Neurol*. 1997; 42:699–704. [PubMed: 9392568]
68. Bishop S, Matheus MG, Abboud MR, et al. Effect of chronic transfusion therapy on progression of neurovascular pathology in pediatric patients with sickle cell anemia. *Blood Cells Mol Dis*. 2011; 47:125–8. [PubMed: 21724428]
69. Webb J, Kwiatkowski JL. Stroke in patients with sickle cell disease. *Expert Rev Hematol*. 2013; 6:301–16. [PubMed: 23782084]
70. Setty BN, Stuart MJ, Dampier C, et al. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. *Lancet*. 2003; 362:1450–5. [PubMed: 14602439]
71. Connes P, Verlhac S, Bernaudin F. Advances in understanding the pathogenesis of cerebrovascular vasculopathy in sickle cell anaemia. *Br J Haematol*. 2013; 161:484–98. [PubMed: 23496688]
72. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. *Free Radic Biol Med*. 2008; 44:1506–28. [PubMed: 18261470]
73. Kato GJ, Hsieh M, Machado R, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. *Am J Hematol*. 2006; 81:503–10. [PubMed: 16755569]
74. Merkel KH, Ginsberg PL, Parker JC Jr, Post MJ. Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation. *Stroke*. 1978; 9:45–52. [PubMed: 622745]
75. Rothman SM, Fulling KH, Nelson JS. Sickle cell anemia and central nervous system infarction: a neuropathological study. *Ann Neurol*. 1986; 20:684–90. [PubMed: 3813497]
76. Dowling MM, Lee N, Quinn CT, et al. Prevalence of intracardiac shunting in children with sickle cell disease and stroke. *The Journal of pediatrics*. 2010; 156:645–50. [PubMed: 20022343]
- 77•. Ware RE, Helms RW. Stroke With Transfusions Changing to Hydroxyurea (SWITCH). *Blood*. 2012; 119:3925–32. This prospective, randomized, non-inferiority trial in children with sickle cell anemia and previous stroke compared an alternative treatment (hydroxyurea/phlebotomy) to

standard therapy (transfusions/chelations) for secondary stroke prevention. In an interim analysis, they found fewer recurrent strokes in the standard treatment arm, with no change in liver iron content between the groups, thus prompting early study closure. [PubMed: 22318199]

78. Aygun B, Wruck LM, Schultz WH, et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. *Am J Hematol*. 2012; 87:428–30. [PubMed: 22231377]
79. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. *J Clin Oncol*. 2006; 24:5277–82. [PubMed: 17088567]
80. Mueller S, Sear K, Hills NK, et al. Risk of first and recurrent stroke in childhood cancer survivors treated with cranial and cervical radiation therapy. *Int J Radiat Oncol Biol Phys*. 2013; 86:643–8. [PubMed: 23623405]
81. Bitzer M, Topka H. Progressive cerebral occlusive disease after radiation therapy. *Stroke*. 1995; 26:131–6. [PubMed: 7839383]
82. Morris B, Partap S, Yeom K, et al. Cerebrovascular disease in childhood cancer survivors: A Children's Oncology Group Report. *Neurology*. 2009; 73:1906–13. [PubMed: 19812380]
83. Mueller S, Fullerton HJ, Stratton K, et al. Radiation, atherosclerotic risk factors, and stroke risk in survivors of pediatric cancer: a report from the Childhood Cancer Survivor Study. *Int J Radiat Oncol Biol Phys*. 2013; 86:649–55. [PubMed: 23680033]
84. Haddy N, Mousannif A, Tukenova M, et al. Relationship between the brain radiation dose for the treatment of childhood cancer and the risk of long-term cerebrovascular mortality. *Brain*. 2011; 134:1362–72. [PubMed: 21596770]
85. Campen CJ, Kranick SM, Kasner SE, et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. *Stroke*. 2012; 43:3035–40. [PubMed: 22968468]
86. Dorresteijn LD, Kappelle AC, Scholz NM, et al. Increased carotid wall thickening after radiotherapy on the neck. *Eur J Cancer*. 2005; 41:1026–30. [PubMed: 15862751]
87. Robbins ME, Zhao W. Chronic oxidative stress and radiation-induced late normal tissue injury: a review. *Int J Radiat Biol*. 2004; 80:251–9. [PubMed: 15204702]
88. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Arcadia, CA: Children's Oncology Group; 2008.
89. Kenet G, Lutkhoff LK, Albisetti M, et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. *Circulation*. 2010; 121:1838–47. [PubMed: 20385928]
90. Goldenberg NA, Bernard TJ, Hillhouse J, et al. Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. *Haematologica*. 2013; 98:802–7. [PubMed: 23349301]
91. Joachim E, Goldenberg NA, Bernard TJ, et al. The Methylenetetrahydrofolate Reductase Polymorphism (MTHFR c.677C>T) and Elevated Plasma Homocysteine Levels in a U.S. Pediatric Population with Incident Thromboembolism. *Thromb Res*. 2013
92. Tatum J, Farid H, Cooke D, et al. Mechanical embolectomy for treatment of large vessel acute ischemic stroke in children. *J Neurointerv Surg*. 2013; 5:128–34. [PubMed: 22307540]
93. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. *Stroke*. 2008; 39:1205–12. [PubMed: 18309168]
94. Amlie-Lefond C, Chan AK, Kirton A, et al. Thrombolysis in acute childhood stroke: design and challenges of the thrombolysis in pediatric stroke clinical trial. *Neuroepidemiology*. 2009; 32:279–86. [PubMed: 19223687]
95. Rea D, Brandsema JF, Armstrong D, et al. Cerebral arteriopathy in children with neurofibromatosis type 1. *Pediatrics*. 2009; 124:e476–83. [PubMed: 19706560]
96. Hankinson TC, Bohman LE, Heyer G, et al. Surgical treatment of moyamoya syndrome in patients with sickle cell anemia: outcome following encephaloduroarteriosynangiosis. *J Neurosurg Pediatr*. 2008; 1:211–6. [PubMed: 18352765]
97. Guzman R, Lee M, Achrol A, et al. Clinical outcome after 450 revascularization procedures for moyamoya disease. *Clinical article*. *J Neurosurg*. 2009; 111:927–35. [PubMed: 19463046]

98. Goldenberg NA, Bernard TJ, Fullerton HJ, et al. Antithrombotic treatments, outcomes, and prognostic factors in acute childhood-onset arterial ischaemic stroke: a multicentre, observational, cohort study. *Lancet Neurol.* 2009; 8:1120–7. [PubMed: 19801204]
99. Beslow LA, Kasner SE, Smith SE, et al. Concurrent validity and reliability of retrospective scoring of the Pediatric National Institutes of Health Stroke Scale. *Stroke; a journal of cerebral circulation.* 2012; 43:341–5.
100. Bernard TJ, Manco-Johnson MJ, Lo W, et al. Towards a consensus-based classification of childhood arterial ischemic stroke. *Stroke; a journal of cerebral circulation.* 2012; 43:371–7.

Table 1

Risk factors for arterial ischemic stroke in children reported in the Great Ormond Street Hospital series, the International Pediatric Stroke Study and the Kaiser Pediatric Stroke Study.

	Ganesan et al. [16]	IPSS [19]	KPSS [37]	
	N=212*	N=674*	N=126	
	N (%)	N (%)	N (%)	OR (CI)
Cardiac Disorders	26 (12)	204 (31)	10 (8)	7.5 (2.4–23.9)
Infection	43 (37)	165 (24)	50 (40)	13.2 (3.6–11.4)
Prothrombotic Disorders	24 (11)	87 (13)	N/A	N/A
Head and Neck Trauma	23 (11)	70 (11)	15 (12)	1.6 (2.9–19.3)
Sickle Cell Disease	35 (17)	39 (6)	2 (2)	N/A
Genetic Disorders/IEM	3 (1)	34 (5)	N/A	N/A
Cancer	7 (3)	33 (5)	N/A	N/A
Autoimmune/Inflammatory	2 (0.9)	4 (0.6)	13 (0.5)	39 (5.1–298)

* Denominators for reported risk factors categories vary slightly.

Abbreviations: IEM - Inborn errors of metabolism; IPSS – International pediatric stroke study; KPSS – Kaiser pediatric stroke study.